Novartis Health (06606.HK): Annual sales exceeded expectations and receivables continued to accelerate
Novartis Health (6606.HK): The 2023 performance continues to exceed expectations, and the volume of Changweiqing's benchmark hospitals can be expected
Nuohui Health-B (06606.HK): Revenue side e-commerce channel volume and repayment progress exceeds expectations
Novartis Health (06606.HK): A pioneer in early cancer screening, the sea of stars sets sail by wind
Novartis Health (06606.HK): Inaugural Investor Open Day deepens business logic in all aspects
Nuohui Health (06606.HK): The product continues to release rapidly and is a leader in early cancer screening and can be expected in the future
NEW HORIZON(6606.HK):BUYBACK COMES AS EXPECTED
NEW HORIZON HEALTH(06606.HK):SALES RAMP UP
Nuohui Health (6606.HK): Outstanding performance, turning losses into profits, and continuing to rise in volume and price of the three major products
Research Report Nuggets | Zhongtai Securities: Nuohui Health's interim results have exceeded expectations, and the three major products are expected to accelerate sales and maintain the “buy” rating
Zhongtai Securities: Maintaining Novo Hui Health's (06606) “Buy” Rating The first half of the year's performance exceeded expectations, and the three major products continued to grow at a high rate
Big Bank Ratings丨Goldman Sachs: Novo Hui Health's interim results increased dramatically, raising sales guidelines for FY23 to 1.7 billion yuan to buy” rating
Major Bank Ratings | UBS: Lowering Novi Health's Target Price to HK$40 Rating “Buy”
Hong Kong stock changes丨Novartis Health rose nearly 8%, receiving Goldman Sachs's target price increase to HK$54.5
Dongwu Securities: First offer to Novartis Health (06606) with a target price of HK$65.66 for the “buy” rating
Novartis Health (06606.HK): A sea of stars can be expected to lead early cancer screening
Novartis Health (6606.HK): 2022 results exceeded expectations and joined forces with Medici Health to promote Gong Zengqing's listing in Hong Kong
Changes in Hong Kong stocks | Novartis Health—B rises 4% next Monday, “B” officially picks “B” and receives Goldman Sachs's target price increase to HK$57.7
Novartis Health-B (06606.HK): Product performance increased significantly, leading the Blue Ocean market for early cancer screening
Goldman Sachs: Maintains Novartis Health-B (06606) “Buy” rating target price to HK$55.9
No Data